Group 5C: HER2+ Breast Cancer; Clinical Trials; Treatment De-escalation

Name: Group 5C: HER2+ Breast Cancer; Clinical Trials; Treatment De-escalation
Start: 2023-12-15
End: 2023-12-15

Poster #PO2-20-01: The STOP-HER2 trial: A phase 2 study of stopping trastuzumab – outcomes in patients with her2+ metastatic breast cancer (TBCRC 062).

Poster #PO3-04-03: Drug holidays in patients with HER-2 positive metastatic breast cancer.